IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-62423-4.html
   My bibliography  Save this article

A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19

Author

Listed:
  • Jung Ho Kim

    (Yonsei University College of Medicine)

  • Sungmin Kym

    (Chungnam National University School of Medicine)

  • Shin-Woo Kim

    (Kyungpook National University)

  • Dae Won Park

    (Ansan-si)

  • Ki Tae Kwon

    (Kyungpook National University)

  • Jun-Won Seo

    (Dong-gu)

  • Seungjin Yu

    (Dankook University
    Dankook University)

  • Goeun Choi

    (Dankook University
    Dankook University)

  • Sanoj Rejinold N

    (Dankook University)

  • Jin-Ho Choy

    (Dankook University
    The National Academy of Sciences)

  • Geun-woo Jin

    (LTD)

  • Jun Yong Choi

    (Yonsei University College of Medicine)

Abstract

Effective and reliable treatments for SARS-CoV-2 infections are a key part of global COVID-19 management. Based on vitro studies, niclosamide has been considered as a potential drug candidate for SARS-CoV-2, but its clinical development has been limited due to poor solubility and bioavailability. Here we report results from a randomized, double-blind, placebo-controlled clinical trial involving 300 patients (Clinical Trial Registration Number: KCT0007307) that assessed the efficacy and safety of the niclosamide nanohybrid CP-COV03 at two different doses. Oral CP-COV03 was well tolerated, with no serious adverse events reported in any treatment group. The primary endpoints demonstrated that CP-COV03 significantly alleviated all 12 FDA-recommended COVID-19 symptoms, with symptom improvement sustained for more than 48 h. Additionally, CP-COV03 reduced SARS-CoV-2 viral load by 56.7% within 16 h of the initial dose compared to baseline. Secondary endpoints, including time to sustained symptom resolution, time to return to usual health, and reduction in hospitalization risk, also showed favorable results in the CP-COV03 group compared to placebo. These findings indicate that CP-COV03 is a safe and effective therapeutic option for the treatment of mild to moderate COVID-19 and represents a promising advancement in the repurposing of niclosamide through nanohybrid engineering.

Suggested Citation

  • Jung Ho Kim & Sungmin Kym & Shin-Woo Kim & Dae Won Park & Ki Tae Kwon & Jun-Won Seo & Seungjin Yu & Goeun Choi & Sanoj Rejinold N & Jin-Ho Choy & Geun-woo Jin & Jun Yong Choi, 2025. "A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19," Nature Communications, Nature, vol. 16(1), pages 1-9, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62423-4
    DOI: 10.1038/s41467-025-62423-4
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-62423-4
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-62423-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Joseph F. Standing & Laura Buggiotti & Jose Afonso Guerra-Assuncao & Maximillian Woodall & Samuel Ellis & Akosua A. Agyeman & Charles Miller & Mercy Okechukwu & Emily Kirkpatrick & Amy I. Jacobs & Cha, 2024. "Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    2. Nils C. Gassen & Daniela Niemeyer & Doreen Muth & Victor M. Corman & Silvia Martinelli & Alwine Gassen & Kathrin Hafner & Jan Papies & Kirstin Mösbauer & Andreas Zellner & Anthony S. Zannas & Alexande, 2019. "SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection," Nature Communications, Nature, vol. 10(1), pages 1-16, December.
    3. Neda Jalali & Hilde K. Brustad & Arnoldo Frigessi & Emily A. MacDonald & Hinta Meijerink & Siri L. Feruglio & Karin M. Nygård & Gunnar Rø & Elisabeth H. Madslien & Birgitte Freiesleben de Blasio, 2022. "Increased household transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variants," Nature Communications, Nature, vol. 13(1), pages 1-5, December.
    4. Jia Wei & Nicole Stoesser & Philippa C. Matthews & Tarnjit Khera & Owen Gethings & Ian Diamond & Ruth Studley & Nick Taylor & Tim E. A. Peto & A. Sarah Walker & Koen B. Pouwels & David W. Eyre, 2024. "Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    5. John Tam & Therwa Hamza & Bing Ma & Kevin Chen & Greg L. Beilhartz & Jacques Ravel & Hanping Feng & Roman A. Melnyk, 2018. "Host-targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota," Nature Communications, Nature, vol. 9(1), pages 1-11, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Denis Mongin & Nils Bürgisser & Gustavo Laurie & Guillaume Schimmel & Diem-Lan Vu & Stephane Cullati & Delphine Sophie Courvoisier, 2023. "Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    2. Leonardo Angeli & Constantino Pereira Caetano & Nicolas Franco & Pietro Coletti & Christel Faes & Geert Molenberghs & Philippe Beutels & Steven Abrams & Lander Willem & Niel Hens, 2025. "Assessing the role of children in the COVID-19 pandemic in Belgium using perturbation analysis," Nature Communications, Nature, vol. 16(1), pages 1-14, December.
    3. Junya Sunagawa & Hyeongki Park & Kwang Su Kim & Ryo Komorizono & Sooyoun Choi & Lucia Ramirez Torres & Joohyeon Woo & Yong Dam Jeong & William S. Hart & Robin N. Thompson & Kazuyuki Aihara & Shingo Iw, 2023. "Isolation may select for earlier and higher peak viral load but shorter duration in SARS-CoV-2 evolution," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    4. Korryn Bodner & Linwei Wang & Rafal Kustra & Jeffrey C. Kwong & Beate Sander & Hind Sbihi & Michael A. Irvine & Sharmistha Mishra, 2025. "Impact of unequal testing on vaccine effectiveness estimates across two study designs: a simulation study," Nature Communications, Nature, vol. 16(1), pages 1-15, December.
    5. Kailey Fischer & Joanne M. Langley & Robyn Harrison & Samira Mubareka & Jeya Nadarajah & Marek Smieja & Louis Valiquette & Curtis Cooper & Jeff Powis & CCS Working Group & Allison McGeer & Brenda L. C, 2024. "Recent Vaccination Against SARS-CoV-2 Is Associated with Less Severe Disease in Working-Age Adults," IJERPH, MDPI, vol. 21(11), pages 1-11, November.
    6. Leslie R. Zwerwer & Tim E. A. Peto & Koen B. Pouwels & Ann Sarah Walker, 2025. "Identification of undetected SARS-CoV-2 infections by clustering of Nucleocapsid antibody trajectories," Nature Communications, Nature, vol. 16(1), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62423-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.